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Abstract
Background: Surgery is the only curative treatment for intraabdominal and retroperitoneal sarcoma (IaRS). Little is
known about how to treat patients with recurrence. We here report the outcome in primary and recurrent
sarcoma treated at the Sarcoma Center in Aarhus, Denmark.
Methods: All patients evaluated for IaRS from June 1998 to May 2008 were enrolled and data on symptoms, signs,
means of diagnosis, extent of surgery, perioperative complications, mortality and long time survival were registered.
Primary and first-recurrence sarcomas were analyzed separately.
Results: Sixty-five of 73 primary and 22 of 28 first-recurrence IaRS had surgery. Fifty-three (82%) and 11 (50%)
patients achieved radical R0 resection. Age and radicality of surgery were independent predictors of death, while
recurrence of sarcoma was not. Perioperative mortality was 2.3%. 5-year survival was 70.2% for primary and 51.8%
for first-recurrent sarcomas. However, patients with radical surgery had 5-year survival of over 70% in both the
primary and recurrent group.
Conclusions: The radicality of surgery is the most important prognostic factor. Patients with recurrence have an
equally good prognosis as those with primary sarcoma if radicality is achieved and such surgery should not be
considered only as a palliative effort.
Background
Soft tissue sarcomas are a heterogeneous group of
malignant tumors originating from mesenchymal cells.
They constitute just under 1% of all cancers [1], corre-
sponding to only 9000 new cases annually in US, and
1500 in UK [1,2]. Approximately 20% of soft tissue sar-
comas arise from intraabdominal or retroperitoneal cells
[3], and the three most prevalent histopathological types
are gastrointestinal stromal tumor (GIST), leiomyosar-
coma, and liposarcoma [4-6]. However, any mesenchy-
mal cell, is capable of malignant transformation, and
more than 100 different histopathological types of
sarcoma have been described [7,8].
Diagnosing intraabdominal and retroperitoneal sarco-
m a s( I a R S )i so f t e nd i f f i c u l ts i n c et h es i g n sa n d
symptoms are often discreet and uncharacteristic. Gen-
eral symptoms are common, and depending on tumor
site, haemorrhage, ascites, pressure symptoms, and pain
m a yb ep r e s e n t .C o n s e q u e n t l y, the diagnosis is often
made at an advanced stage when the tumor has reached
a considerable size.
The final diagnosis is usually made by imaging modal-
ities such as MR-, CT-, or ultrasound scans. It is recom-
mended, that preoperative biopsies are performed using
a fine needle because of the risk of spreading through
tumor seeding, also considering the puncture route
[9,10]. The literature on outcome in particular in recur-
rent sarcomas with modern surgical treatment is scarce.
The aim of the present prospective cohort study is to
report the outcome of surgical treatment of primary as
well as recurrent sarcoma in our center over the last
10 years.
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From June 1998 to May 2008 all patients over 18 years of
age with IaRS examined at the sarcoma center at the sur-
gical department P, Aarhus University Hospital, were
registered consecutively. The center is a large elective
surgery department which also has extensive experience
with other forms of advanced abdominal surgery proce-
dures. It covers specialized surgical functions for western
Denmark, an area with approximately 2 million inhabi-
tants. During this period, all peripheral surgical depart-
ments in the area began referring sarcoma patients to the
center for diagnosis, evaluation, and surgery.
Data on primary and recurrent tumor were collected
including preoperative symptoms and diagnostic meth-
ods. Patients with primary sarcoma or any first recur-
rence of sarcoma were included in the statistical analysis
while patients with more than one recurrence were
excluded from the study. In the following, the term
recurrent disease refers to patients having their first
recurrent disease unless otherwise stated. Variables
related to the pre-, peri- and postoperative period were
collected and included: Age, gender and symptoms, pre-
operative diagnosis, preoperative biopsy (yes/no), metas-
tasis (yes/no), site of origin, preoperative medical
treatment, tumour (primary/1st recurrence), operability
(operable/inoperable), resection of adjacent organs, radi-
cality (R0 = macro- and microscopically radical resec-
tion, R1 = macroscopically, but not microscopically
radical, and R2 = macroscopical residual tumour tissue,
local or distant), histopathological diagnosis, postopera-
tive complications, and perioperative mortality, as well
as longterm survival. None of the tumors types (includ-
ing GIST tumors) received neoadjuvant treatment. R1
and R2 GIST tumors received Imatinib as palliative
treatment. R1 and R2 liposarcomas were also offered
palliative treatment.
Since 1968, all Danish residents have been assigned a
unique 10-digit personal identification number by the Cen-
tral Office of Civil Registration. Patients are identified by
this number during all contacts with the healthcare system.
Likewise, all deaths are registered using this number. Thus,
we were able to trace the exact date of death for every
patient. Patients were also linked with all hospital discharge
registries which collect data of hospitalizations since 1977.
Patients were followed until 31 December 2008.
We registered a total of 114 contacts in 96 patients. Of
the 114 contacts, 73 presented with a primary tumor while
28 had a first recurrence of tumor. 13 of the contacts had
second- or more recurrencies and were excluded, so the
population included in the analysis was 73 primary and 28
recurrent sarcomas for a total of 101 contacts.
Sixty-five of 73 (89%) primary sarcomas had surgery,
and 22 of 28 (79%) patients with recurrent disease were
considered operable (p = 0.11). Of these 87 operations,
R0- resection was achieved in 51 of 65 (78%) of the
patients with primary tumor and 11 of 22 (50%) of the
patients with first-recurrence (p < 0.01).
Histopathologically, 39% of IaRS were GIST, liposarco-
mas constituted 18%, whereas relatively few leiomyosar-
comas were found (11%). Thirty percent of the tumors
had a different histological type than these three types.
These consisted of more than 20 different rare histo-
pathological types (Data not shown).
Median time of follow-up was 2.94 years (interquartile
range: 0.97-4.65). Baseline characteristics are shown in
Table 1. All operations were performed by the same
3 surgeons.
Statistical analyses
For primary and recurrent sarcomas, we compared cate-
gorical variables using Chi2 test or, if not applicable,
Fisher’s exact test. Continuous variables were analysed
by twoway t-test. Time at risk was calculated as days
f r o mt h ed a t eo fs u r g e r yt oe n do ff o l l o w - u p .W ec o n -
structed Kaplan-Meier survival plots of 5 year mortality
and used a log rank test to test for differences between
curves. We performed univariate Cox’ regression ana-
lyses to find predictors for death, using time since date
of surgery as the time scale. Variables identified in the
univariate analysis as predictors of mortality (using
p-value ≤ 0.1 as cutoff) were entered into a multivariate
Cox regression model. P-values ≤ 0,05 were considered
statistically significant. All analyses were done using
STATA 9.2 (Statacorp., College Station, Texas, USA).
Results
Short-term outcome
Primary tumors required less extensive surgery than
recurrent tumors and could be removed without resec-
tion of adjacent organs in 34 of 65 patients (52%) com-
pared to 6 of 22 (27%) (p = 0.04). Correspondingly,
resection of two or more organs was necessary in
10 (45%) patients with recurrent tumor and only
7 (11%) with primary tumors (p < 0.001).
In spite of the more extensive and complex surgery,
the rate of postoperative complications in the group
with recurrent sarcoma was very low, and fully compar-
able to that of primary sarcoma (Table 2).
Thirty-day mortality in the recurrent sarcoma group
was zero. In the group with primary sarcoma, 2 patients
died within 30 days of surgery. For the two groups com-
bined, the 30 day mortality was 2.3% (CI: 0.3-8.1%)
Long-term outcome
The 5-year survival rate for patients with a primary
tumor was 70.2% (CI:0.56-0.81) compared to 51.8%
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Primary Tumor (n = 73) 1st Recurrence (n = 28) p
Gender 0.267
Male 39(53%) 11(39%)
Female 34(47%) 17(61%)
Age
Mean years, sd 58.0 ± 15.0 55.1 ± 12.8 0.365
Median 60.0 56.0
Median 25% 50.0 45.5
Median 75% 68.0 61.5
Analgetics* 0.211
None 54 (75%) 16 (59%)
Non-opioids 16 (22%) 9 (33%)
Opioids 2 (3%) 2 (7%)
Enlarged Abdomen* 0.596
No 57 (79%) 20 (74%)
Yes 15 (21%) 7 (26%)
Bleeding* 0.126
No 50 (69%) 25 (93%)
Intraabdominal 5 (7%) 0
Upper GI 5 (7%) 0
Lower GI 12 (17%) 2 (7%)
Obstruction* 1.000
No 60 (83%) 23 (85%)
Postprandial pain 7 (10%) 2 (7%)
Ileus 5 (7%) 2 (7%)
Palpable abdominal mass* 0.647
No 29 (40%) 9 (32%)
Yes 43 (59%) 17 (61%)
Metastases*
No 69 (95%) 20 (71%) 0.010
Yes 3 (4%) 6 (21%)
* Exact data not available on all patients
Table 2 Postoperative complications
Primary Tumor (n = 65) 1st Recurrence (n = 22)
Anastomosis
Number of anastomosis 25 10
Reoperation due to leakage 1 (4%) 0
Other intraabdminal complications
Bleeding 3 (5%) 3 (14%)
Abscess 0 0
Other 3 (5%) 0
Wound complications
Infection 4 (6%) 0
Wound dehiscense 3 (5%) 1 (5%)
Cardiopulmonary complications 5 (8%) 3 (14%)
Deep venous thrombosis 2 (3%) 0
Death within 30 days 2 (3%) 0
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0.138) (Figure 1).
The 5 year survival rate for patients with R0-excision
was 76.8% (95% CI: 0.62-0.86) compared to 43.5% (95%
CI: 0.23-0.62) in patients with R1 or R2 excision (p <
0.001) (Figure 2). We found no difference in 5 year sur-
vival rates between patients with GIST (63.4%, 95% CI:
0.44-0.77) and non-GIST tumors (56.9%, 95% CI: 0.42-
0.69, p = 0.29)).
The Kaplan-Meier plot of primary/recurrent and radi-
cal/non-radical surgery is shown in Figure 3. The survi-
val rates of patients having undergone R0 surgery were
similar for primary (77.8% CI: 0.61-0.88) versus recur-
rent sarcoma (71.6% CI 0:.35-0.90). Accordingly, in the
multivariate model only age 70+ HR 4.49 (95% CI: 1.78-
11.3) and radicality HR 4.39 (95% CI: 1.80-10.7)
remained significant predictors of death. Recurrent dis-
ease was not an independent predictor of death, no was
location or histopathology (GIST/non-GIST).
Discussion
In patients with IaRS that generally require extensive
surgery the best results are expected to be achieved by a
multidisciplinary team involving surgeons, radiologists,
onchologists, and pathologists in an experienced treat-
ment center [11-14].
In addition to studying 65 patients undergoing surgery
for primary IaRS, the study includes 22 contacts with
patients with recurrent disease after surgery for IaRS,
providing a unique opportunity to explore the outcome
in these patients. Few publications looking specifically at
this category of patients have been published [4].
In the publications on surgical treatment of IaRS that
report these data, the perioperative mortality in primary
IaRS is between 3 and 7% [7,15-18]. Non-fatal perio-
perative complications are reported in 8-44% [15,18,19].
The mortality in our center was comparably low, only
two patients (2.3%) died within 30 days of surgery and
serious complications were also very rare.
In primary sarcomas, resection of adjacent organs was
necessary in 48%, which is in the same order of magni-
tude as in other reports [7], and radical surgery was
achieved in 78%, also comparable to other centers [7]. As
expected, in patients with recurrent disease after first sur-
gery for IaRS the disease was more advanced. More often,
these patients had metastatic disease and they were
assessed to be non-operable more frequently. Although
basic surgical techniques were respected, macro- and
microscopic radicality was achieved in patients with
more advanced disease less frequently, in 50% of cases. In
spite of the more extensive surgery, however, peri- and
postoperative complications in patients with recurrent
disease were not increased, and the 30-day mortality was
zero, stressing the importance and impact of optimal
intra- and postoperative management.
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Figure 1 5-year survival after surgery for intraabdominal or
retroperitoneal sarcoma comparing primary and first
recurrence sarcomas.
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Figure 2 5-year survival after surgery for intraabdominal or
retroperitoneal sarcoma comparing radical (R0) and non-
radical (R1 + R2) surgery.
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Figure 3 5-year survival after surgery for intraabdominal or
retroperitoneal sarcoma comparing primary and first
recurrence sarcomas undergoing radical (R0) and non-radical
(R1 + R2) surgery. Radicality, but not whether the sarcoma is
primary or recurrent, is essential for survival.
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cations varied considerably
in other studies, the 5-year survival was remarkably
consistent, about 50-55% [13,15-18]. Our
survival rate for primary IaRS was 70.2%, well in line
with others. In earlier publications,
surgery for recurrent IaRS has been considered pallia-
tive [16]. We found a 5-year survival in
recurrent IaRS of 51.8%, but when looking specifically
at those recurrent tumors where
radical excision was achieved, the 5-year survival rose
to 71.6%, similar to the survival
rate of primary sarcomas with radical excision. The
fact that the radicality of the surgery is
such an important prognostic factor is in line with the
conclusions in other studies [4,16,19,20].
To conclude, even when primary curative surgery fails,
secondary surgery for recurrent IaRS results in a 51.8%
5-year survival, increasing to 71.6% if a radical resection
can be achieved. As such, recurrent disease has the
same prognosis as primary if radical surgery is achieved,
indeed radicality but not primary/recurrent disease is an
independent predictor of death. However, secondary
surgery for recurrent sarcoma is often more extensive
involving resection of adjacent organs. For such a treat-
ment to be carried through, it is crucial to keep the fre-
quency of peri- and post-operative complications as low
as possible, and we report that this can be achieved in a
highly specialized surgical center.
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